Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Cloppenburg – page 11

191 clinical trials in Cloppenburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Cloppenburg at a glance
191
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

191 trials in Cloppenburg

Open in trial search

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Migraine

Not recruiting

Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study on Durvalumab and Chemotherapy for Patients with Resectable Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitaetsklinikum Essen AöR

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Opnurasib
  • Sponsor:Novartis Pharma AG

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Sonelokimab for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Plasma cell myeloma

Not recruiting

Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Universitaetsklinikum Ulm AöR

Cholangiocarcinoma+3

Not recruiting

Study of Durvalumab, Tremelimumab, and Capecitabine for Patients with Biliary Tract Cancer in an Adjuvant Setting

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Cloppenburg

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on hyperlipoproteinemia and cardiovascular disease management through advanced therapeutic approaches. Research evaluates long-term safety and effectiveness of treatments for patients requiring lipoprotein apheresis.

  • Lipid Management
  • Cardiovascular Disease Prevention
  • Therapeutic Safety Assessment

These trials aim to improve treatment options for patients with elevated lipoprotein levels and established cardiovascular conditions.

02 Nephrology Studies

Groundbreaking research investigating treatments for IgA Nephropathy, focusing on preventing progressive loss of renal function. The studies evaluate novel therapeutic approaches for managing proteinuria in affected patients.

  • Renal Function Protection
  • Proteinuria Management
  • Disease Progression Prevention

Clinical investigations aim to advance treatment options for patients with kidney disorders through targeted therapeutic approaches.

03 Treatment Optimization

Comprehensive evaluation of therapeutic interventions across multiple medical conditions, with a focus on long-term safety profiles and treatment effectiveness. Studies include both controlled trials and extension phases.

  • Long-term Safety Monitoring
  • Treatment Tolerability
  • Patient Outcomes Assessment

Research efforts are directed at optimizing treatment protocols and improving patient care standards.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.